# US 10,441,556 B2 · Composition containing glibenclamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,556 B2
- Document ID: US10441556B2
- Status: Granted
- Kind: B2
- Application number: 15/989,738
- Filed: 2018-05-25
- Published: 2018-09-27
- Granted: 2019-10-15
- Earliest claimed: 2006-10-12
- Assignees: Biogen Chesapeake LLC
- Applicants: Biogen Chesapeake LLC
- Inventors: Sven Martin Jacobson; Robert Ang
- Web page: https://patentgrep.com/patent/US10441556B2

## CPC

- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/175: having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time. Exemplary pharmaceutical compositions include compositions including glibenclamide and memantine; glibenclamide and donepezil; tolbutamide and memantine; tolbutamide and donepezil; and these compositions further including glucagon and/or glucose.

## Claims

### Claim 1

A composition suitable for intravenous administration comprising glibenclamide or a pharmaceutically acceptable salt thereof, mannitol, and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a compound effective to increase blood plasma glucose levels.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said compound is glucose or glucagon.

### Claim 4 (depends on 1)

The composition of claim 1, further comprising dextrose.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said composition is a single dose composition containing from 0.1 to 15 mg glibenclamide or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said composition is a single dose composition containing from 0.1 to 5 mg glibenclamide or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said composition is a single dose composition containing from 0.1 to 1 mg glibenclamide or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The composition of claim 1, further comprising NaCl.

### Claim 9 (depends on 1)

The composition of claim 1, further comprising KCl.

### Claim 10 (depends on 1)

The composition of claim 1, further comprising CaCl2.

### Claim 11 (depends on 1)

The composition of claim 1, further comprising lactate.